RECRUITING

Brain Metabolism Observed at 7 Tesla

Talk to us

Conditions

Glut1 Deficiency Syndrome 1Glucose Metabolism DisordersEpilepsyGlut1 Deficiency Syndrome 1, Autosomal RecessiveGlucose Transporter Type 1 Deficiency SyndromeGlucose Transporter Protein Type 1 Deficiency SyndromeGlucose Transport Defect

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal is to develop methodology to monitor flux in the citric acid cycle in brain via 13C nuclear magnetic resonance (NMR) spectroscopy at 7 Tesla.

Official Title

Brain Metabolism Observed at 7 Tesla in Health and Metabolic Disease.

Quick Facts

Study Start:2022-05-03
Study Completion:2026-09-20
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05085704

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:16 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:CHILD, ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Adolescents and adults with previously documented diagnosis of Glut1 Deficiency with diagnosis genetically confirmed or confirmed by PET scan of the brain.
  2. 2. Ages 16 to 65
  3. 3. Persons with dental fillings, dental crowns, and short (max.4 cm) dental retainer wires can be included.
  1. 1. People or patients with uncontrolled seizure disorder, defined as grand mal (not absence) seizure in the preceding 3 months.
  2. 2. Pregnant females will be excluded. A serum or urine pregnancy test will be administered to all females of child bearing potential within 24 hours of administration of the tracer and MRI scan. The pregnancy test will be communicated in person by the study PI. Positive results in subjects 17 years old or younger will be disclosed to parent/guardian only.
  3. 3. Subjects with typical implanted orthopedic metal in bone may be considered for inclusion in a 7T scan providing the implant is not within the volume of the radio frequency coil. The PI and the AIRC Medical Director will discuss each case and determine eligibility.
  4. 4. Persons with ICD, pacemakers, neurostimulators and other such devices will be excluded.
  5. 5. Persons with claustrophobia are excluded.
  6. 6. Persons with questionable ferrous implants, bullets, BB's, and shrapnel will be excluded.
  7. 7. Subjects who are not fluent in English will be excluded because immediate cooperation and the ability to respond to instructions from the investigators are necessary.

Contacts and Locations

Study Contact

Juan M Pascual, M.D.
CONTACT
214-648-4591
rare.diseases@utsouthwestern.edu
Adrian Avila, B.S.
CONTACT
214-648-4591
rare.diseases@utsouthwestern.edu

Study Locations (Sites)

UT Southwestern Medical Center
Dallas, Texas, 75390
United States

Collaborators and Investigators

Sponsor: University of Texas Southwestern Medical Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-05-03
Study Completion Date2026-09-20

Study Record Updates

Study Start Date2022-05-03
Study Completion Date2026-09-20

Terms related to this study

Additional Relevant MeSH Terms

  • Glut1 Deficiency Syndrome 1
  • Glucose Metabolism Disorders
  • Epilepsy
  • Glut1 Deficiency Syndrome 1, Autosomal Recessive
  • Glucose Transporter Type 1 Deficiency Syndrome
  • Glucose Transporter Protein Type 1 Deficiency Syndrome
  • Glucose Transport Defect